Amphastar Pharmaceuticals (AMPH) FCF Margin (2013 - 2026)

Amphastar Pharmaceuticals has reported FCF Margin for 14 years, with the latest figure at 23.24% in Q2 2026.

• On a quarterly basis, FCF Margin rose 889.0% year-over-year to 23.24% in Q2 2026; TTM through Jun 2026 was 20.94%, a 542.0% increase from a year earlier, with the FY2025 full-year figure at 16.84%, down 670.0% from the prior year.
• FCF Margin was 23.24% for Q2 2026 at Amphastar Pharmaceuticals, up from 22.39% in the prior quarter.
• The five-year high for FCF Margin was 36.6% in Q1 2022, with the low at 2.09% in Q2 2022.
• Average FCF Margin over 5 years is 19.56%, with a median of 22.23% recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: FCF Margin plunged 2807 bps in 2022, then soared 3357 bps in 2023.
• Over 5 years, FCF Margin stood at 6.6% in 2022, then gained by 23 bps to 8.1% in 2023, then increased by 10 bps to 8.91% in 2024, then surged by 51 bps to 13.43% in 2025, then surged by 73 bps to 23.24% in 2026.
• The last three FCF Margin figures came in at 23.24% (Q2 2026), 22.39% (Q1 2026), and 13.43% (Q4 2025), per Business Quant data.